These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
589 related articles for article (PubMed ID: 36891310)
21. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. Parikh RH; Lonial S CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265 [TBL] [Abstract][Full Text] [Related]
22. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports. Xu J; Ming X; Wang C; Xu B; Xiao Y Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974 [TBL] [Abstract][Full Text] [Related]
23. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Van Oekelen O; Nath K; Mouhieddine TH; Farzana T; Aleman A; Melnekoff DT; Ghodke-Puranik Y; Shah GL; Lesokhin A; Giralt S; Thibaud S; Rossi A; Rodriguez C; Sanchez L; Richter J; Richard S; Cho HJ; Chari A; Usmani SZ; Jagannath S; Shah UA; Mailankody S; Parekh S Blood; 2023 Feb; 141(7):756-765. PubMed ID: 36327160 [TBL] [Abstract][Full Text] [Related]
24. Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β. Alabanza LM; Xiong Y; Vu B; Webster B; Wu D; Hu P; Zhu Z; Dropulic B; Dash P; Schneider D Front Immunol; 2022; 13():832645. PubMed ID: 35222421 [TBL] [Abstract][Full Text] [Related]
25. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J Front Immunol; 2021; 12():755866. PubMed ID: 34777368 [TBL] [Abstract][Full Text] [Related]
26. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? D'Agostino M; Raje N Leukemia; 2020 Jan; 34(1):21-34. PubMed ID: 31780814 [TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597 [TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities. Ho M; Zanwar S; Paludo J Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132 [TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. Ma T; Shi J; Liu H Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373 [TBL] [Abstract][Full Text] [Related]
30. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. García-Guerrero E; Sierro-Martínez B; Pérez-Simón JA Front Immunol; 2020; 11():1128. PubMed ID: 32582204 [TBL] [Abstract][Full Text] [Related]
32. SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions. Biltibo E; Berdeja JG Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):310-321. PubMed ID: 36925390 [TBL] [Abstract][Full Text] [Related]
33. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. Yang J; Zhou W; Li D; Niu T; Wang W Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149 [TBL] [Abstract][Full Text] [Related]
34. CAR T-cell therapy in multiple myeloma: more room for improvement. Teoh PJ; Chng WJ Blood Cancer J; 2021 Apr; 11(4):84. PubMed ID: 33927192 [TBL] [Abstract][Full Text] [Related]
35. CAR T-cell therapy for multiple myeloma: state of the art and prospects. van de Donk NWCJ; Usmani SZ; Yong K Lancet Haematol; 2021 Jun; 8(6):e446-e461. PubMed ID: 34048683 [TBL] [Abstract][Full Text] [Related]
36. Current state and next-generation CAR-T cells in multiple myeloma. Manier S; Ingegnere T; Escure G; Prodhomme C; Nudel M; Mitra S; Facon T Blood Rev; 2022 Jul; 54():100929. PubMed ID: 35131139 [TBL] [Abstract][Full Text] [Related]
37. Cellular therapy for multiple myeloma: what's now and what's next. Rodriguez-Otero P; San-Miguel JF Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):180-189. PubMed ID: 36485132 [TBL] [Abstract][Full Text] [Related]
38. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S Front Immunol; 2019; 10():1613. PubMed ID: 31379824 [TBL] [Abstract][Full Text] [Related]